Davis, CA: Botanical Solution Inc. (BSI), innovator of sustainable, highly consistent and cost effective Advanced Botanical Materials, has successfully secured $3.3 million in a seed round of funding, and is planning another round of funding for Spring 2021.
The Spring 2021 Round of funding will boost BSI’s proven ability to discover and develop novel botanical products that are sustainable, highly consistent and cost effective. BSI’s proprietary biotechnology platform eliminates the major barriers, such as supply and quality issues, which have prevented traditional botanicals from becoming commercially successful.
BSI’s first commercially successful product is the biofungicide BotriStop®, which is based on a tree native to Chile, the Quillaja saponaria. The seed round of funding is supporting product production and sales growth of BotriStop biofungicide initially in Chile through BSI’s distribution partner Syngenta. BotriStop will soon be registered in a number of key Latin American countries and regulatory progress is expected in the U.S. and E.U. during 2021.
BSI’s in-lab growth capabilities for Quillaja saponaria plants using biotechnology processes will serve additional purposes, such as the sustainable production of billions of doses of the ‘Gold Standard’ adjuvant QS-21, currently used in Covid-19 and other vaccines. QS-21 has been in relatively short supply due to strict deforestation laws in Chile… but thanks to BSI’s proprietary technique for extracting this human immune system activator when the trees are in vitro, this Company can meet worldwide demand for QS-21 right from its own laboratories, and do so without harming any trees.
BSI has a breakthrough technology for the cost-effective and reliable production of high quality botanicals for agriculture and pharma, filling critical gaps in these markets. We are currently addressing key strategic and distribution issues, and are well-positioned to solve major problems in the areas of sustainable agriculture and large scale production and reliable supply of QS-21 for pharma.CEO Gastón Salinas
BSI plans to become a major supplier of pharmaceutical grade QS-21 to address the serious challenges presented by the imminent shortage of this key vaccine adjuvant.
BSI received $3.3 million in funding from multiple organizations, most recently including the International Development Bank (IDB). Other investors include Inmobiliaria e Inversiones el Coigue, El Viento, Sociedad de Invesiones Celta, The Yield Lab Business Accelerator, Ganeshalab Business Accelerator, Sembrador Capital, and ‘angel investors’ Ignacio Smith and Wolfgang Schuch.
BSI, a Delaware Corporation has a proprietary R&D platform for sustainable and improved production of consistent, high quality Advanced Botanical Materials (ABM). ABM-01 is the first ABM produced by the company, based on a plant called Quillaja saponaria. ABM-01 is the active ingredient used in two gold standard products, BSI’s biopesticide BotriStop® and the adjuvant QS-21, used in modern vaccine development. To learn more visit www.botanical-solution.com